Cerebellar Ataxia: Clinical Trials

18 trials for Cerebellar Ataxia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 4 active not recruiting, 4 terminated. 18 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 318Completed 10, Active not recruiting 4, Terminated 4
Phase 24Completed 3, Terminated 1

Follow Cerebellar Ataxia: new trials by email Literature Review of Cerebellar Ataxia trials Research Report on Cerebellar Ataxia

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pivotal Study of N-acetyl-L-leucine for CACNA1A
N-Acetyl-L-Leucine, Placebo - CACNA1A, Spinocerebellar Ataxia Type 6
Phase 3Active not recruitingIntraBio Inc602026-08-172026-11-03
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
N-Acetyl-L-Leucine, Placebo - Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
Phase 3Active not recruitingIntraBio Inc602025-03-182026-11-04
Open-Label Extension of EryDex Study IEDAT-04-2022
Dexamethasone sodium phosphate - Ataxia Telangiectasia
Phase 3TerminatedQuince Therapeutics S.p.A.1012024-12-112026-05-05
Evaluate the Neurological Effects of EryDex on Subjects With A-T
Dexamethasone sodium phosphate, Placebo - Ataxia Telangiectasia
Phase 3CompletedQuince Therapeutics S.p.A.1052024-06-242026-04-30
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
SLS-005, Placebo - Spinocerebellar Ataxia Type 3
Phase 2 / Phase 3TerminatedSeelos Therapeutics, Inc.232022-06-032024-04-24
Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
Tllsh2910, Placebo - Ataxia, Cerebellar, Multiple System Atrophy
Phase 3TerminatedNational Taiwan University Hospital182019-04-022023-04-07
Troriluzole in Adult Participants With Spinocerebellar Ataxia
troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Phase 3Active not recruitingBiohaven Pharmaceuticals, Inc.2992019-03-082026-06-24
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
EryDex System - Ataxia Telangiectasia, Genetic Syndrome
Phase 3TerminatedQuince Therapeutics S.p.A.1042018-06-122024-10-08
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
Riluzole, Placebo - Spinocerebellar Ataxia Type 2
Phase 3CompletedAssistance Publique - Hôpitaux de Paris422018-01-172021-06-21
Open Pilot Trial of BHV-4157
BHV-4157 - Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Phase 3Active not recruitingUniversity of California, Los Angeles242017-12-152024-05-09
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
Troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1
Phase 2 / Phase 3CompletedBiohaven Pharmaceuticals, Inc.1412016-12-152025-10-08
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
KPS-0373, High dose, KPS-0373, Low dose, Placebo - Spinocerebellar Degeneration
Phase 3CompletedKissei Pharmaceutical Co., Ltd.3742013-10-092018-12-14
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
Lithium Carbonate, Placebo - Spinocerebellar Ataxia Type 3, Machado Joseph Disease
Phase 2 / Phase 3CompletedHospital de Clinicas de Porto Alegre622011-05-012013-01-30
Efficacy of Riluzole in Hereditary Cerebellar Ataxia
riluzole, Placebo comparator - Cerebellar Ataxia
Phase 2 / Phase 3CompletedS. Andrea Hospital602010-04-012015-04-21
Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)
Conjugated pneumococcal vaccine (Prevenar) - Ataxia Telangiectasia (AT)
Phase 3CompletedInstitute of Child Health302006-06-012008-04-11
A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
KPS-0373, High dose, KPS-0373, Low dose - Spinocerebellar Degeneration
Phase 3CompletedKissei Pharmaceutical Co., Ltd.2016-04-18
A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
KPS-0373, High dose, KPS-0373, Low dose - Spinocerebellar Degeneration
Phase 3CompletedKissei Pharmaceutical Co., Ltd.2016-04-18
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
KPS-0373, High dose, KPS-0373, Low dose - Spinocerebellar Degeneration
Phase 3CompletedKissei Pharmaceutical Co., Ltd.2016-04-18

Narrower conditions

Spinocerebellar Ataxias (11)  ·  Ataxia Telangiectasia (5)  ·  Machado-Joseph Disease (4)  ·  Spinocerebellar Degenerations (4)  ·  Ataxia (1)  ·  Episodic Ataxia, Type 2 (1)  ·  Friedreich Ataxia (1)  ·  Genetic Diseases, Inborn (1)  ·  Heart Arrest (1)  ·  Multiple System Atrophy (1)  ·  Spinocerebellar Ataxia 10 (1)  ·  Spinocerebellar ataxia 8 (1)

Broader conditions

Brain Diseases (18)  ·  Central Nervous System Diseases (18)  ·  Cerebellar Diseases (18)  ·  Dyskinesias (18)  ·  Nervous System Diseases (18)  ·  Neurologic Manifestations (18)  ·  Ataxia (17)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17)  ·  Genetic Diseases, Inborn (16)  ·  Neurodegenerative Diseases (13)  ·  Heredodegenerative Disorders, Nervous System (12)  ·  Spinal Cord Diseases (12)  ·  Spinocerebellar Degenerations (8)  ·  Cardiovascular Diseases (6)

Interventions

Riluzole (2)  ·  acetylleucine (2)  ·  dexamethasone 21-phosphate (2)  ·  Heptavalent Pneumococcal Conjugate Vaccine (1)  ·  IB1001 (1)  ·  Lithium Carbonate (1)

Sponsors

Kissei Pharmaceutical Co., Ltd. (4)  ·  Quince Therapeutics S.p.A. (3)  ·  Biohaven Pharmaceuticals, Inc. (2)  ·  IntraBio Inc (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  Institute of Child Health (1)  ·  National Taiwan University Hospital (1)  ·  S. Andrea Hospital (1)  ·  Seelos Therapeutics, Inc. (1)  ·  University of California, Los Angeles (1)

Countries

United States (9)  ·  United Kingdom (7)  ·  Germany (6)  ·  Italy (5)  ·  Spain (5)  ·  Japan (4)  ·  Switzerland (4)  ·  Norway (3)  ·  Poland (3)  ·  Australia (2)  ·  Brazil (2)  ·  Denmark (2)  ·  Austria (1)  ·  Belgium (1)  ·  China (1)

Top investigators

Dirk Thye, MD (2)  ·  Chun-Hwei Tai (1)  ·  Guenter R Janhofer, MD, PhD (1)  ·  Jonas AM Saute, MD (1)  ·  Laura B Jardim, MD PhD (1)  ·  Silvia Romano, MD, PhD (1)  ·  Tatsuro Takei (1)

Results publications

PMID 34115419, PMID 24399647, PMID 26297649, PMID 26321318, PMID 31937586, PMID 35063116, PMID 38814532, PMID 39806095, PMID 39917433, PMID 42309084, PMID 42600624

NIH funding

2017 (1), 2018 (1), 2025 (1)